Ipilimumab for the treatment of metastatic prostate cancer

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. [PubMed 20296855].
   Web of Science ®Google Scholar
• Silvestri I, Cattarino S, Giantulli S, et al. A perspective of immunotherapy for prostate cancer. Cancers. 2016;8:64.
   Web of Science ®Google Scholar
• Sarwar S, Majid AMA, Nyamath P, et al. Biomarkers of prostatic cancer: an attempt to categorize patients into prostatic carcinoma, benign prostatic hyperplasia, or prostatitis based on serum prostate specific antigen, prostatic acid phosphatase, calcium, and phosphorus. Prostate Cancer. 2017;1:Article ID 5687212–7.
   Web of Science ®Google Scholar
• Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59(1):110–118.
   PubMed Web of Science ®Google Scholar
• Moreno JG, O’Hara SM, Gross S, et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology. 2001;58(3):386–392.
   PubMed Web of Science ®Google Scholar
• Heninger E, Krueger TE, Thiede SM, et al. Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget. 2016;7(51):84359–84374.
   PubMed Web of Science ®Google Scholar
• Boccellino M, Alaia C, Misso G, et al. Gene interference strategies as a new tool for the treatment of prostate cancer. Endocrine. 2015;49(3):588–605.
   PubMed Web of Science ®Google Scholar
• Vanacore D, Boccellino M, Rossetti S, et al. Micrornas in prostate cancer: an overview. Oncotarget. 2017;8(30):50240–50251.
   PubMed Web of Science ®Google Scholar
• Wang Z, Xu L, Hu Y, et al. miRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer. Sci Rep. 2016;6:25602.
   PubMed Web of Science ®Google Scholar
• Borghese C, Casagrande N, Pivetta E, et al. Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells. Oncotarget. 2017;8(26):42926–42938.
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Achberger S, Aldrich W, et al. Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor. J Immunother. 2012;35(7):587–594.
   PubMed Web of Science ®Google Scholar
• Galore-Haskel G, Nemlich Y, Greenberg E, et al. A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget. 2015:6:30.
   Web of Science ®Google Scholar
• Cheng ML, Fong L. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol. 2014;15(1):115–126.
   PubMed Web of Science ®Google Scholar
• Ojima I, Lichtenthal B, Lee S, et al. Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat. 2016;26(1):1–20.
   PubMed Web of Science ®Google Scholar
• Cardillo I, Spugnini EP, Galluzzo P, et al. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. Future Oncol. 2013;9(9):1375–1388.
   PubMed Web of Science ®Google Scholar
• Silvestri I, Cattarino S, Aglianò AM, et al. Beyond the immune suppression: the immunotherapy in prostate cancer. Biomed Res Int. 2015;7:Article ID 794968.
   Web of Science ®Google Scholar
• Cha E, Small EJ. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?. Cancer Med. 2013;2(2):243–252.
   PubMed Web of Science ®Google Scholar
• May KF Jr., Gulley JL, Drake CG, et al. Prostate cancer immunotherapy. Clin Cancer Res. 2011;17(16):5233–5238.
   PubMed Web of Science ®Google Scholar
• Modena A, Ciccarese C, Iacovelli R, et al. Immune checkpoint inhibitors and prostate cancer: a new frontier?. Oncol Rev. 2016;10:293.
   PubMed Web of Science ®Google Scholar
• Quinn DI, Shore ND, Egawa S, et al. Immunotherapy for castration resistant prostate cancer: progress and new paradigms. Urol Oncol. 2015;33:245–260.
   PubMed Web of Science ®Google Scholar
• Westdorp H, Sköld AE, Snijer BA, et al. Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol. 2014. DOI:10.3389/fimmu
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J. 2013;19(1):50–58.
   PubMed Web of Science ®Google Scholar
• Finkelstein SE, Salenius S, Mantz CA, et al. Combining immunotherapy and radiation for prostate cancer. Clin Genitourin Cancer. 2015;13(1):1–9.
   PubMed Web of Science ®Google Scholar
• Kalina JL, Neilson DS, Comber AP, et al. Immune modulation by androgen deprivation and radiation therapy: implications for prostate cancer immunotherapy. Cancers. 2017;9:13.
   Web of Science ®Google Scholar
• Alberti C. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. G Chir. 2016;37(5):225–235.
   Web of Science ®Google Scholar
• Nardone V, Botta C, Caraglia M, et al. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. Cancer Biol Ther. 2016;17(11):1213–1220.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8(3):410–416.
   PubMed Web of Science ®Google Scholar
• Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7(33):52810–52817.
   PubMed Web of Science ®Google Scholar
• Keler T, Halk E, Vitale L, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol. 2003;171(11):6251–6259.
   PubMed Web of Science ®Google Scholar
• Morse MA. Technology evaluation: ipilimumab, medarex/bristol-myers squibb. Curr Opin Mol Ther. 2005;7(6):588–597.
   PubMedGoogle Scholar
• Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23(4):741–750.
   PubMed Web of Science ®Google Scholar
• Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950–5956.
   PubMed Web of Science ®Google Scholar
• Feng Y, Masson E, Dai D, et al. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol. 2014;78(1):106–117.
   PubMed Web of Science ®Google Scholar
• Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810–1815.
   PubMed Web of Science ®Google Scholar
• Slovin SF, Hamid O, Tejwani S, et al. Ipilimumab in metastatic castrate-resistant prostate cancer: results from an open-label, multicenter phase I/II study. J Clin Oncol. 2012;30(S5). abstr 25.
   Google Scholar
• Kwon TM, Drake CG, Scher HI, et al. Ipi versus placebo after radiotherapy in patients with metastatic castration resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 June;15(7):700–712.
   PubMed Web of Science ®Google Scholar
• Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase iii trial of ipi versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–47.
   PubMed Web of Science ®Google Scholar
• Cabel L, Loir E, Gravis G, et al. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. Immunotherapy. 2017;5:31.
   Web of Science ®Google Scholar
• van den Eetwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony stimulating factor-transduced allogeneic prostate cancer cells and ipi in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509–517.
   PubMed Web of Science ®Google Scholar
• Gao J, He Q, Subudhi S, et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. 2015;34(43):5411–5417.
   PubMed Web of Science ®Google Scholar
• Wanchoo R, Karam S, Uppal NU, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45:160–169.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–647.
   PubMed Web of Science ®Google Scholar
• Carl D, Grullich C, Hering S, et al. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC Res Note. 2015;26(8):316.
   Google Scholar
• Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24:1813–1821.
   PubMed Web of Science ®Google Scholar
• Small E, Higano C, Tchekmedyian N, et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J Clin Oncol (Meeting Abstracts). 2006;24(suppl):4609.
   Google Scholar
• Tollefson M, Karnes R, Thompson R, et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer [abstract 168]. Presented at the Genitounirary Cancers Symposium; San Francisco, California. 2010; 5–7.
   Google Scholar
• Fong L, Kwek SS, O’Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009;69:609–615.
   PubMed Web of Science ®Google Scholar
• Gerritsen W, van den Eertwegh AJ, De Gruijl T, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer. MHRPC J Clin Oncol. 2006;24:Suppl:Abstr 2500.
   Google Scholar
• Mohebtash M, Madan RA, Arlen PM, et al. Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2009;27(15S):5144.
   PubMedGoogle Scholar
• Singh BH, Gulley JL. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl. 2014;16:364–371.
   PubMed Web of Science ®Google Scholar
• Boikos SA, Antonarakis ES. Immunotherapy for prostate cancer enters its golden age. Clin Med Insights: Oncol. 2012;6:263–273.
   PubMedGoogle Scholar
• Scholz M, Yep S, Chancey M, et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipi in progressive metastatic castrate-resistant prostate cancer. ImmunoTargets Ther. 2017;6:11–16.
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, et al. Evaluation of Ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382–389.
   PubMed Web of Science ®Google Scholar
• Met O, Wang M, Pedersen AE, et al. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett. 2006;231:247–256.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Johnston RJ, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One. 2016;11(9):e0161779.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.
   PubMed Web of Science ®Google Scholar
• Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015;8:123.
   PubMed Web of Science ®Google Scholar
• Chris Fellner. Ipilimumab (Yervoy) prolongs survival in advanced melanoma serious side effects and a hefty price tag may limit its use. P T.. 2012;37(9):503–530.
   PubMedGoogle Scholar